` AMGN (Amgen Inc) vs S&P 500 Comparison - Alpha Spread

AMGN
vs
S&P 500

Over the past 12 months, AMGN has outperformed S&P 500, delivering a return of 12% compared to the S&P 500's 2% drop.

Stocks Performance
AMGN vs S&P 500

Loading

Performance Gap
AMGN vs S&P 500

Loading
AMGN
S&P 500
Difference

Performance By Year
AMGN vs S&P 500

Loading
AMGN
S&P 500
Add Stock

Competitors Performance
Amgen Inc vs Peers

S&P 500
AMGN
ABBV
GILD
VRTX
CSL
Add Stock

Amgen Inc
Glance View

Economic Moat
Wide
Market Cap
158.1B USD
Industry
Biotechnology

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
256.48 USD
Overvaluation 13%
Intrinsic Value
Price
Back to Top